Mr. David Johnson is a biopharmaceutical business leader with more than 25 years of experience in drug development. He is currently Chief Executive Officer and founder of Solve Therapeutics, a venture-backed start-up focusing on developing next-generation mAb-based oncology therapeutics. In late 2021, the company closed a $126 million Series A financing.
Prior to founding Solve Therapeutics, Mr. Johnson served as Chief Executive Officer at VelosBio, which Merck acquired for $2.75 billion in late 2020. Before VelosBio, Mr. Johnson was Chief Executive Officer at Acerta Pharma, where he led the company through a critical phase of growth from early to late-stage clinical development. Mr. Johnson and his leadership team ultimately led the acquisition of Acerta by AstraZeneca in a deal valued at $7 billion.
Prior to Acerta, Mr. Johnson held roles of increasing responsibility with Calistoga (acquired by GILD), Gloucester (acquired by CELG), MLMN (acquired by TAK), Immunex (acquired by AMGN), and Roche. He has raised over $700 million in biopharma capital and delivered transactions valued at over $10 billion.
In addition to Aura’s Board, Mr. Johnson serves on the Board of Directors of Palleon Pharmaceuticals and Lengo Therapeutics (recently acquired by BPMC). He also serves as the Chairman of the Board of Directors of Zentalis Pharmaceuticals, a publicly traded clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancer.
What is David Michael Johnson's net worth?
The estimated net worth of David Michael Johnson is at least $1.07 million as of May 16th, 2025. Mr. Johnson owns 166,167 shares of Aura Biosciences stock worth more than $1,071,777 as of December 4th. This net worth approximation does not reflect any other investments that Mr. Johnson may own. Learn More about David Michael Johnson's net worth.
How do I contact David Michael Johnson?
Has David Michael Johnson been buying or selling shares of Aura Biosciences?
David Michael Johnson has not been actively trading shares of Aura Biosciences over the course of the past ninety days. Most recently, on Friday, May 16th, David Michael Johnson bought 20,000 shares of Aura Biosciences stock. The stock was acquired at an average cost of $4.90 per share, with a total value of $98,000.00. Following the completion of the transaction, the director now directly owns 166,167 shares of the company's stock, valued at $814,218.30. Learn More on David Michael Johnson's trading history.
Who are Aura Biosciences' active insiders?
Are insiders buying or selling shares of Aura Biosciences?
In the last twelve months, Aura Biosciences insiders bought shares 2 times. They purchased a total of 70,000 shares worth more than $343,000.00. In the last twelve months, insiders at the sold shares 13 times. They sold a total of 79,568 shares worth more than $514,201.11. The most recent insider tranaction occured on November, 17th when insider Janet Jill Hopkins sold 17,109 shares worth more than $92,730.78. Insiders at Aura Biosciences own 6.3% of the company.
Learn More about insider trades at Aura Biosciences. Information on this page was last updated on 11/17/2025.
